MCBÜ Açıkerişim Sistemi :: Browsing by Author "Demir B."

Browsing by Author "Demir B."

Now showing 1 - 14 of 14

Molybdenum oxide/platinum modified glassy carbon electrode: A novel electrocatalytic platform for the monitoring of electrochemical reduction of oxygen and its biosensing applications
(2013) Çakar I.; Özdokur K.V.; Demir B.; Yavuz E.; Demirkol D.O.; Koçak S.; Timur S.; Ertaş F.N.
The reduction of oxygen to water is one of the most important reactions in electrochemistry with regards to the wide range of applications in electrocatalysis, metal corrosion, and fuel cell and mostly in biosensor studies. Present study describes the use of a glassy carbon electrode modified with platinum and molybdenum oxide (Pt-MoOx) in strongly acidic solutions for electrocatalytic reduction of oxygen dissolved in buffer solution for the first time. The dispersion of Pt nanoparticles on MoOx provides larger surface area and better electrocatalytic activity for oxygen reduction and the best response toward dissolved oxygen was obtained with a mole ratio of 1:90 Pt:Mo in deposition solution. The modified surface was then used as a biosensing platform for the monitoring of oxygen consumption due to the bio-catalytic action of glucose oxidase (GOx) as the model enzyme. After optimization of the operational conditions, analytical characterization and application of the glucose oxidase GOx biosensor to flow injection analysis mode have been successfully performed. © 2013 Published by Elsevier B.V. All rights reserved.
A novel ethanol biosensor on pulsed deposited MnOx-MoOx electrode decorated with Pt nanoparticles
(Elsevier B.V., 2016) Ozdokur K.V.; Demir B.; Atman E.; Tatli A.Y.; Yilmaz B.; Demirkol D.O.; Kocak S.; Timur S.; Ertas F.N.
Transition metal oxides provide low cost alternatives to noble metals due to their unique electrocatalytic and electrochromic properties and display strong interactions with noble metal nanoparticles. Present study describes the use of mixed molybdenum and manganese oxide film electrode enriched with platinum nanoparticles to enhance the catalytic performance in the oxygen reduction reaction (ORR). The mixed oxide film, denominated as GCE/MnOx-MoOx/Pt, was co-deposited by pulsed potential deposition technique and then, it was used as an immobilization matrix for the intact bacterial cells. The resulted whole cell biosensor has served as a sensing platform for ethanol detection by monitoring of oxygen consumption as a result of the bacterial metabolism in the presence of the substrate. Following the optimization experiments, GCE/MnOx-MoOx/Pt/Gluconobacter oxydans biofilm was applied to investigate the analytical characteristics and response time to ethanol as well as operational stability and substrate specificity for other carbon sources. The linear range was found as 0.075–5.0 mM with a response time of 63 s and the developed method was applied to the ethanol determination in alcoholic drinks. Satisfactory recovery figures were obtained in comparison to the standard method. © 2016 Elsevier B.V.
A multicentre prospective analysis of the incidence of pemphigoid diseases in Turkey
(John Wiley and Sons Inc, 2021) Durdu M.; Bozca B.C.; Enli S.; Yazıcı Özgen Z.; Yaylı S.; Aktan Ş.; Mutlu D.; Erturan I.; Ayvaz Çelik H.H.; Melikoğlu M.; Pala E.; Gürsel Ürün Y.; Harman M.; Şavk E.; Işık S.; Duygulu Ş.; İmren I.G.; Fettahlıoğlu Karaman B.; Kaya Erdoğan H.; Kılıç A.; Özçelik S.; Inan K.; Yılmaz M.A.; Şanlı H.E.; Kalay Yıldızhan İ.; Mülayim M.K.; Çiçek D.; Demir B.; Yasak Güner R.; Baykal Selçuk L.; Gündüz K.; Daye M.; Borlu M.; Solak E.O.; Dizman D.; Güneş B.; Ozkur E.; Polat M.; Eskiocak A.H.; Uzun S.
Background: The differentiation between the pemphigoid diseases is essential for treatment and prognosis. In Turkey, data on the incidence of these diseases are insufficient. Our aim in this study is to determine the incidence, demographics and clinical characteristics associated with diseases of the pemphigoid group. Methods: We prospectively analysed 295 patients with pemphigoid who visited dermatology clinics of tertiary referral hospitals in 12 different regions of Turkey within a year. The diagnosis was based on clinical, histopathological, direct immunofluorescence (DIF) and serological (multivariant enzyme-linked immunosorbent assay [ELISA], indirect immunofluorescence and mosaic-based BIOCHIP) examinations. Clinical and demographic findings, aetiological factors and concomitant diseases observed in the patients were recorded. Results: A total of 295 (female/male ratio: 1.7/1) patients with pemphigoid were diagnosed in 1-year period. The overall incidence rate of pemphigoid diseases was found to be 3.55 cases per million-years. The ratio of pemphigoid group diseases to pemphigus group diseases was 1.6. The most common pemphigoid type was bullous pemphigoid (BP, 93.2%). The others were epidermolysis bullosa acquisita (3.1%), pemphigoid gestationis (2.4%), linear IgA disease (1%) and mucous membrane pemphigoid (0.3%). The most common (26.8%) possible trigger of the bullous pemphigoid was gliptin derivative drugs. The most common concomitant diseases with pemphigoid were cardiovascular (27.8%) and neurological diseases (23.7%). Conclusions: This study showed that the increased frequency of bullous pemphigoid reversed the pemphigoid/pemphigus ratio in Turkey. Further studies are warranted regarding the reasons for this increase. © 2021 The Australasian College of Dermatologists
Oxidative stress in patients with carbon monoxide poisoning
(Ankara Yildirim Beyazit University, 2021) Celik G.K.; Günaydin G.P.; Demir B.; Yilmaz M.; Ersen T.; Tuncay M.E.; Kavakli H.S.
Objectives: Oxidative stress refers to formation of more reactive oxygen species (ROS) than that are eliminated by cellular defense mechanisms (antioxidants). The aim of this study is to determine oxidative stress developed in CO poisoning, to measure oxidant and antioxidant parameters and to study the effects of the NBO and HBO treatments on these parameters. Materials and Methods: On admission to emergency department and at the end of 24th hour after the oxygen therapy, total oxidant status (TOS) was measured as an oxidative stress parameter, total antioxidant status (TAS), paraoxonase (PON), serum paraoxonase (SPON), arylesterase (ARES), and thiol (TTL) levels were measured as indicators of antioxidant capacity. Results: TAS, TTL and ARES levels were found to be significantly lower in the patient group when compared to control group. There were no differences in both inital and 24th hour levels of oxidative stress parameters between the patients who received hyperbaric therapy and normobaric therapy. Conclusion: Continuing decrease of TAS, PON, SPON, ARES, and TTL may be because the antioxidant capacity has not yet been replaced or reperfusion ischemia is caused by treatment. The results of our study support that oxidative balance turns against antioxidants in cases of CO poisoning. Copyright © 2021 The Authors.
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
(Springer Science and Business Media Deutschland GmbH, 2022) Gürbüz M.; Kutlu Y.; Akkuş E.; Köksoy E.B.; Köse N.; Öven B.B.; Uluç B.O.; Demiray A.G.; Erdem D.; Demir B.; Turhal N.S.; Üskent N.; Akbaş S.; Selçukbiricik F.; İnal A.; Bilici A.; Ölmez Ö.F.; Çabuk D.; Ünal Ç.; Hızal M.; Şendur M.A.N.; Korkmaz M.; Karadurmuş N.; Ertürk İ.; Göksu S.S.; Tatlı A.M.; Güven D.C.; Kılıçkap S.; Paksoy N.; Aydıner A.; Çınkır H.Y.; Özkul Ö.; Öztürk A.; Ballı S.; Kemal Y.; Erdoğan A.P.; Er Ö.; Yumuk P.F.; Demirkazık A.
Purpose: Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods: This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results: A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1–8) and atezolizumab cycle was 7 (1–32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7–7.8), and 11.9 months (95%CI 11–12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion: This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Prognostic value of lactate to hematocrit ratio score in patients with severe thoracoabdominal trauma; [Ciddi torakoabdominal travma hastalarında laktat-hematokrit oranının prognostik değeri]
(Turkish Association of Trauma and Emergency Surgery, 2022) Demir B.; Şaşmaz M.İ.; Saglam Gurmen E.; Bilge A.
BACKGROUND: Significant portion of trauma-related deaths occur in the 1st h; therefore, rapid diagnosis and adequate resuscitation in trauma patients are essential preventing mortality. In this study, we aimed to evaluate the role of lactate-to-hematocrite ratio (LHR) score for predicting mortality in patients with severe thoracoabdominal trauma. METHODS: In this retrospective, cross-sectional study, we evaluated patients who applied to the emergency room between January 1, 2016, and December 31, 2019, due to multiple trauma. We measured the blood gas analysis values and LHR score of patients with severe thoracoabdominal trauma included in the study and investigated the effectiveness of the LHR score in predicting mortality. RESULTS: 106 patients with severe thoracoabdominal trauma were included in the study. The 30-day mortality rate of the patients was 42.5% (n=45). Considering the 30-day mortality rates, the initial hematocrit, lactate, base deficit, and LHR score were statistically different between patients who died and survived. When the cutoff value for the LHR score was taken as 0.187 on the ROC curve to distinguish mortality, the sensitivity was found to be 77.8%, specificity to be 90.2%. CONCLUSION: LHR score is an effective parameter with high sensitivity and specificity in predicting mortality in patients with severe thoracoabdominal trauma. © 2022 Turkish Association of Trauma and Emergency Surgery.
Systemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy
(College of Physicians and Surgeons Pakistan, 2022) Ekinci F.; Balcik O.Y.; Demir B.; Gursoy P.; Ozveren A.; Erdogan A.P.
Objective: To evaluate the prognostic significance of the new index designed by formulating neutrophil, lymphocyte, and platelet counts in patients with metastatic disease receiving immune checkpoint inhibitors (ICI) and its effect on the immune-related adverse events (irAEs). Study Design: Cohort study. Place and Duration of Study: Department of Medical Oncology, University of Manisa Celal Bayar, University of Aydin Adnan Menderes, and University of Ege, and Izmir Kent Hospital, Turkey, from January 2016 to April 2020. Methodology: Patients with metastatic disease receiving ICI sufficient follow-up data were included. Patients, who had received treatment for a minimum of 3 months, were evaluated for the response. Systemic immune-inflammation index (SII) was calculated as neutrophil (/L) × (lymphocyte (/L) / platelet (/L). The cut-off value was determined by examining the area under the receiver operating characteristic (ROC) curve for the SII value. The endpoints of this study included overall survival (OS) and progression-free survival (PFS). Results: A total of 168, patients who received ICI in the metastatic stage, were evaluated. The OS of the patients with low SII scores was 110.8 months (95% CI, 88.2-133.5), while patients with high SII scores were 36.0 months (95% CI, 28.4-43.6) and reached statistical significance (p <0.001). The results of univariate (HR=3.376, 95% CI, 1.986-5.739, p<0.001 and multivariate (HR=2.792, 95% CI, 1.495-5.215, p=0.011) analyses were statistically significant as well. Conclusion: The SII score in patients with metastatic disease receiving ICI was closely related to the prognosis. Patients with a high SII score are associated with a worse prognosis, these patients develop fewer irAEs. © 2022 College of Physicians and Surgeons Pakistan. All rights reserved.
Factors Predicting Response in Breast Cancer Receiving Neoadjuvant Therapy and the Role of Ki67 Labeling Index
(College of Physicians and Surgeons Pakistan, 2023) Ekinci F.; Uzun M.; Demir B.; Unek I.T.; Erdogan A.P.
Objective: To determine the predictive value of Ki67 on pathological complete response (pCR) of breast and axilla regions in breast cancer (BC) patients receiving neoadjuvant therapy (NAT). Study Design: Descriptive study. Place and Duration of the Study: Departments of Medical Oncology, Sirnak State Hospital, Aydin State Hospital, Manisa Celal Bayar University, and Dokuz Eylul University, from November 2010 to July 2022. Methodology: PCR and various histopathological parameters were evaluated for BC patients receiving NAT. The Youden Index method was used to find the cut-off value for the Ki67 variable according to the receiver operating characteristic (ROC) curve. This value was obtained as 77.5. Breast and axillary responses were individually evaluated to assess response to NAT. Univariate and multivariate logistic regression analysis were used to predict both breast and axillary pCR. Results: A total number of 280 females receiving NAT for BC were included in the study. Multivariate analysis for breast pCR to NAT showed that Ki67 index (>77.5 vs <77.5, p=0.047) was statistically significant marker. While Ki67 index was significant for breast pCR in both univariate and multivariate analyses, the same was not observed on axillary response (p=0.387). Conclusion: High Ki67 level was significantly associated with breast pCR in BC patients receiving NAT, but a similar effect was not observed on axillary pCR. These findings suggest that breast and axilla tissues have a biological differences in treatment responses. © 2023 College of Physicians and Surgeons Pakistan. All rights reserved.
HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer
(College of Physicians and Surgeons Pakistan, 2023) Acar O.; Ayhan M.; Demir B.; Ekinci F.; Aytac A.; Erdogan A.P.
Objective: To investigate the effect of the haemoglobin, albumin, lymphocyte, and platelet (HALP) score (Haemoglobin, Albumin, Lymphocyte, Platelet count) on survival as a new prognostic factor in metastatic bladder cancer. Study Design: Descriptive study. Place and Duration of the Study: Department of Medical Oncology, Celal Bayar University, Manisa, Turkey, and Adnan Menderes University, Aydin, Turkey, from 2010 to 2020. Methodology: The medical charts of patients with metastatic bladder cancer were reviewed retrospectively. Prognostic value of the HALP score as a marker of overall survival was examined through a receiver operating characteristic (ROC) curve analysis. Results: The cut-off value for the HALP score in the ROC curve analysis was 29. The median overall survival (OS) was 19 months when the HALP score was less than 29, and the median OS was 40 months when the HALP score was 29 or greater, and this finding was statistically significant (p = 0.003). Conclusion: The HALP score is closely related to prognosis in metastatic bladder cancer. A high HALP score is associated with better survival outcomes. © 2023 College of Physicians and Surgeons Pakistan. All rights reserved.
Nationwide prospective audit for the evaluation of appendicitis risk prediction models in adults: Right iliac fossa treatment (RIFT) - Turkey
(Oxford University Press, 2024) Yalcinkaya A.; Yalcinkaya A.; Balci B.; Keskin C.; Erkan I.; Yildiz A.; Kamer E.; Leventoglu S.; Caglikulekci M.; Zarbaliyev E.; Sevmis M.; Ulgen Y.; Altinel Y.; Meric S.; Akbas A.; Hacim N.A.; Vartanoglu Aktokmanyan T.; Aktimur Y.E.; Calikoglu F.; Gullu H.F.; Durma A.G.; Acar S.; Ciftci E.; Balik E.; Kulle C.B.; Ozata I.H.; Tufekci T.; Tatar C.; Sevinc M.M.; Sevik H.; Ertürk C.; Kiraz I.N.; Ozben V.; Aytac E.; Aliyeva Z.; Mutlu A.U.; Tanal M.; Celayir M.F.; Bozkurt E.; Yetkin S.G.; Ergin E.; Attaallah W.; Uprak T.K.; Omak A.; Simsek O.; Bozkurt M.A.; Kara Y.; Bozdag E.; Yirgin H.; Ozcan A.; Okkabaz N.; Ozdenkaya Y.; Haksal M.C.; Pekuz C.K.; Duru S.; Sivrikoz E.; Ozdemir Y.; Tan N.; Yarbug Karayali F.; Taghiyeva A.; Tirnova I.; Erenler Bayraktar I.; Bayraktar O.; Emsal E.Z.; Dalkilic M.I.; Yesiltas M.; Tok H.; Karakas D.O.; Pusane A.; Demirer A.I.; Sahin H.B.; Gok A.F.K.; Bozkurt H.A.; Yildirim M.; Uzunyolcu G.; Yanar H.T.; Ergun S.; Kutluk F.; Uludag S.S.; Zengin A.K.; Ozcelik M.F.; Sanli A.N.; Altuntas Y.E.; Memisoglu E.; Sari R.; Akdogan O.; Kucuk H.F.; Ozkan O.F.; Ulgur H.S.; Kirkan E.F.; Yuksekdag S.; Rencuzogullari A.; Aktas M.K.; Aba M.; Demirel A.O.; Eray I.C.; Aydogan B.; Cetinkunar S.; Yener K.; Sozutek A.; Irkorucu O.; Bayrak M.; Altintas Y.; Alabaz O.; Atasever A.; Erdogrul G.; Kupeli A.H.; Muhammedoglu B.; Kokdas S.; Kaya M.; Uysal E.; Yildirim A.C.; Zeren S.; Ekici M.F.; Algin M.C.; Kucuk G.O.; Eraslan H.; Aybar E.; Polat S.; Ceylan A.; Isik O.; Kural S.; Aktas A.; Bakar B.; Uzunoglu M.Y.; Gulcu B.; Ozturk E.; Devay A.O.; Taspinar E.; Balcin O.; Aksoy F.; Garip G.; Yalkin O.; Iflazoglu N.; Yigit D.; Kaya R.B.; Ugur M.; Kilic E.; Dedemoglu A.; Arslan R.E.; Temiz M.; Aydin C.; Demirli Atici S.; Kaya T.; Ozturk S.; Calik B.; Kilinc G.; Acar T.; Acar N.; Cengiz F.; Ureyen O.; Tan S.; Ilhan E.; Turk Y.; Durak A.T.; Yilmaz M.; Mercan M.; Atci R.; Sokmen S.; Bisgin T.; Egeli T.; Yildirim Y.; Safak T.; Celik K.; Yilmaz E.M.; Kirnap M.; Demirkiran A.E.; Sekerci U.U.; Karacan E.; Bilgic E.; Ozmen M.M.; Guldogan C.E.; Gundogdu E.; Moran M.; Erol T.; Dincer H.A.; Kirimtay B.; Yilmaz S.; Cennet O.; Yildiz A.; Sahin C.; Akyol C.; Koc M.A.; Ersoz S.; Turhan A.; Konca C.; Tezcaner T.; Erkent M.; Aydin O.; Avci T.; Altiner S.; Osmanov I.; Emral A.C.; Cetinkaya G.; Lapsekili E.; Sakca M.; Cimen S.; Ozen D.; Kozan E.B.; Dogan L.; Haberal E.; Kayhan O.; Aksel B.; Karabacak H.; Azili C.; Yazici F.; Apaydin M.; Kaya I.O.; Cetinkaya E.; Akin T.; Gunes G.; Turap H.; Aslan D.; Demirbag A.E.; Bolukbasi B.; Karaca B.E.; Ozturk E.; Ozeller E.; Kayacan G.S.; Borcek A.O.; Ece I.; Yormaz S.; Colak B.; Calisir A.; Sahin M.; Arslan K.; Hasirci I.; Ulutas M.E.; Metin S.H.; Gultekin F.A.; Ozkan Z.; Ilhan O.; Gundogdu T.; Liman R.K.; Kanat B.H.; Aydin A.; Sungurtekin U.; Ozgen U.; Aykota M.R.; Altintoprak F.; Gonullu E.; Cakmak G.; Dulger U.C.; Mantoglu B.; Demir H.; Akin E.; Eroz E.; Nazli O.; Dere O.; Dadasoglu M.A.; Kara E.; Tutcu S.; Solak I.; Gencer I.; Dalkiran A.; Sevinc B.; Karahan O.; Damburaci N.; Sari E.; Akay T.; Calta A.F.; Ozdemir A.; Ohri N.; Ermis I.; Bozbiyik O.; Ozdemir M.; Goktepe B.; Demir B.; Kilincarslan O.; Gunduz U.R.; Olcum M.; Dincer O.I.; Cakir R.C.; Dinc B.; Sahin E.; Uludag E.; Arslan Y.; Posteki G.; Oktay A.; Tatar O.C.; Guler S.A.; Utkan N.Z.; Tayar S.; Copelci Y.; Kartal M.; Kalayci T.; Yeni M.; Buyukkasap A.C.; Vural S.; Kesicioglu T.; Aydin I.; Gulmez M.; Saracoglu C.; Topcu O.; Kurt A.; Soylu S.; Kurt B.; Serin M.; Basceken S.I.; Gundes E.; Savda M.; Balkan A.Z.A.; Yildiz M.N.; Uzunkoy A.; Karaca E.; Berkan A.; Isik A.; Yildiz Y.A.; Ergul Z.; Yasar N.F.; Badak B.; Ozen A.; Velipasaoglu M.; Ure I.
Background: Appendicitis is the most prevalent surgical emergency. The negative appendicectomy rate and diagnostic uncertainty are important concerns. This study aimed to assess the effectiveness of current appendicitis risk prediction models in patients with acute right iliac fossa pain. Methods: A nationwide prospective observational study was conducted, including all consecutive adult patients who presented with right iliac fossa pain. Diagnostic, clinical and negative appendicectomy rate data were recorded. The Alvarado score, Appendicitis Inflammatory Response (AIR), Raja Isteri Pengiran Anak Saleha Appendicitis (RIPASA) and Adult Appendicitis Score systems were calculated with collected data to classify patients into risk categories. Diagnostic value and categorization performance were evaluated, with use of risk category-based metrics including 'true positive rate' (percentage of appendicitis patients in the highest risk category), 'failure rate' (percentage of patients with appendicitis in the lowest risk category) and 'categorization resolution' (true positive rate/failure rate). Results: A total of 3358 patients from 84 centres were included. Female patients were less likely to undergo surgery than men (71.5% versus 82.5% respectively; relative risk 0.866, 95% c.i. 0.834 to 0.901, P < 0.001); with a three-fold higher negative appendicectomy rate (11.3% versus 4.1% respectively; relative risk 2.744, 95% c.i. 2.047 to 3.677, P < 0.001). Ultrasonography was utilized in 56.8% and computed tomography in 75.2% of all patients. The Adult Appendicitis Score had the best diagnostic performance for the whole population; however, only RIPASA was significant in men. All scoring systems were successful in females patients, but Adult Appendicitis Score had the highest area under the receiver operating characteristic curve value. The RIPASA and the Adult Appendicitis Score had the best categorization resolution values, complemented by their exceedingly low failure rates in both male and female patients. Alvarado and AIR had extremely high failure rates in men. Conclusion: The negative appendicectomy rate was low overall, but women had an almost three-fold higher negative appendicectomy rate despite lower likelihood to undergo surgery. The overuse of imaging tests, best exemplified by the 75.2% frequency of patients undergoing computed tomography, may lead to increased costs. Risk-scoring systems such as RIPASA and Adult Appendicitis Score appear to be superior to Alvarado and AIR. © 2024 The Author(s). Published by Oxford University Press on behalf of BJS Foundation Ltd.
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
(Springer, 2024) Beypınar İ.; Demir H.; Yaslıkaya Ş.; Köşeci T.; Demir B.; Çolak G.; Ağaoğlu A.B.; Şahbazlar M.; Şancı P.C.; Çabuk D.; Işık U.; Şahin E.; Coşkun A.; Caner B.; Aykut T.; Artaç M.; Duygulu M.E.; Sever N.; Öksüz S.; Turan N.; Aykan M.B.; Tüzün E.K.; Uysal M.; Uğurlu İ.; Sakin A.; Acar C.; Özaşkın D.; Şakalar T.; Keskinkılıç M.; Yavuzşen T.; Köse N.; Ertürk İ.; Yıldırım N.; Balçık O.Y.; Alkan A.; Selvi O.; Erçin E.; Ünal O.Ü.; Karaçin C.
Purpose: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method: The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results: One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion: This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
Reply to Letter to the Editor: "Management of Ventricular Pseudoaneurysms"
(Turkish Society of Cardiology, 2024) Şaşmaz M.İ.; Demir B.; Uçar M.; Avci A.
[No abstract available]
The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
(Nature Research, 2024) Özyurt N.; Alkan A.; Gülbağcı B.; Seyyar M.; Aydın E.; Şahbazlar M.; Türker M.; Kınıkoğlu O.; Yerlikaya T.; Dinç G.; Aytaç A.; Kalkan Z.; Ebinç S.; Gültürk İ.; Keskinkılıç M.; İşleyen Z.S.; Çağlayan D.; Türkel A.; Şakalar T.; Sekmek S.; Yıldırım N.; Koçak S.; Okutur K.; Özveren A.; Dursun B.; Kitaplı S.; Eren O.Ö.; Beypınar İ.; Hacıbekiroğlu İ.; Çabuk D.; Karaman E.; Acar Ö.; Paydaş S.; Eryılmaz M.K.; Demir B.; Oruç Z.; Yılmaz M.; Biricik F.S.; Salim D.K.; Tanrıverdi Ö.; Doğan M.
The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1–3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2–0.6) p < 0.001) and lymph node negativity (HR:0.35 (95% CI 0.1–0.9) p = 0.03) were independent factors for OS. Although there were pathological and clinical differences, the pCR, DFS and OS were similar between Her2-0 and Her2-low TNBC patients. The importance of Her2 status of TNBC in neoadjuvant setting should be further studied. © The Author(s) 2024.
Correction to: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study (Scientific Reports, (2024), 14, 1, (23556), 10.1038/s41598-024-75293-5)
(Nature Research, 2025) Özyurt N.; Alkan A.; Gülbağcı B.; Seyyar M.; Aşık E.; Şahbazlar M.; Türker M.; Kınıkoğlu O.; Yerlikaya T.; Dinç G.; Aytaç A.; Kalkan Z.; Ebinç S.; Gültürk İ.; Keskinkılıç M.; İşleyen Z.S.; Çağlayan D.; Türkel A.; Aydın E.; Şakalar T.; Sekmek S.; Yıldırım N.; Koçak S.; Okutur K.; Özveren A.; Dursun B.; Kitaplı S.; Eren O.Ö.; Beypınar İ.; Hacıbekiroğlu İ.; Çabuk D.; Karaman E.; Acar Ö.; Paydaş S.; Eryılmaz M.K.; Demir B.; Oruç Z.; Yılmaz M.; Biricik F.S.; Salim D.K.; Tanrıverdi Ö.; Doğan M.
Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-024-75293-5, published online 09 October 2024 The original version of this Article contained an error in the spelling of the author Esra Aşık which was incorrectly given as Esra Aydın. The original Article has been corrected. © The Author(s) 2024.

Browsing by Author "Demir B."

Results Per Page

Sort Options